Cannabinoids have an alphabet soup of more than 140 letters, and it’s easy to get lost. An important cannabinoid generated by the Cannabis sativa plant is CBC, or cannabichromene (CBC). Numerous medical applications, a fascinating history, and a fantastic future await this non-addictive cannabinoid.
You shouldn’t expect the same kind of high you get from THC from CBC because it is non-intoxicating. However, this does not imply that you will not notice any changes in your body after using the product. Unlike CB1 receptors, the TPRV1 and TRPA1 receptors have immediate effects. As a result, CBC users may experience feelings of happiness and relaxation.
A rising number of people are turning to CBC for various reasons, including the belief that it has similar effects to CBD.
Uses for Which It Is Therapeutic
Only studies showing statistically significant advantages, backed by scientific evidence, can be considered authentic, no matter how many medicinal uses CBC manufacturers promise. Consumers can’t tell if a product is genuine unless they visit the FDA’s website, where the agency randomly tests items. It is up to the integrity of marketing and manufacturing companies to educate the public, which is difficult at best. CBC has been shown in studies to offer therapeutic advantages for the purposes listed below. You can even visit this link for more information.
- Mood and anxiety disorders
- There is a lot of inflammation and pain.
- Spasms and seizures
Cannabidiol (CBC) has been shown to increase serotonin levels and may encourage the growth of new neurons in the hippocampus, the part of the brain that governs mood and emotions (Campos et al., 2013). Even if preliminary research reveals promising results, CBC manufacturers sell their products with full endorsement. However, human studies have not been finished or are merely anecdotal and not based on rigorous scientific data.
By blocking the 3-glycine receptors, which feel pain in the neurological system, CBC has diminished inflammation and neuropathic pain in laboratory rodents (mice and rats) (Xiong et al., 2012). Despite real worries about side effects and the opioid crisis, CBC can provide comfort without addictive properties and justifies further study.
The FDA first licensed CBC for seizure control after extensive research. CBC has shown encouraging effects in the treatment of insomnia and other forms of chronic stress-related insomnia (Babson et al., 2017). Synthetic cannabidiols, such as dronabinol and nabilone, have treated insomnia and excessive daytime sleepiness. And even nightmares caused by post-traumatic stress disorder (PTSD). However, further longitudinal studies are required to determine the clinical implications of these findings.
By increasing the activity of GABA receptors in the brain, CBC appears to influence the transcription of over 1100 genes that reduce inflammation in the central nervous system. Inflammatory biochemicals and the neurotransmitter glutamate are also down-regulated by them. There are more than 350 molecules that play a role in the inflammatory response, making it difficult to determine precisely how CBC affects this process.
Selective cannabinoids appear to have a minor effect on chronic neuropathy in a notable 2017 study (Meng et al., 2018). Several extensive, well-designed, random controlled studies are needed to analyze different dosages, duration, and effects on physical and psychological function. It is currently lawful in the United States for federally-approved research organizations to conduct cannabis studies.
Researchers at Cochrane Library in 2018 conducted a study and meta-analysis on medical marijuana to see if it could reduce pain intensity, provide moderate pain relief, and improve sleep and psychological distress better than a placebo than any cannabis-based medicine.
They were aware that there was a shortage of high-quality data in this research (Philips et al., 2018). When it came to enhancing the health-related quality of life, they thought cannabis-based medicines were no better than placebos. Study participants were leaving because of adverse effects like tiredness, dizziness, and cognitive issues with cannabis use.
Risks to Health
There are always dangers and side effects associated with prescription medication, so it’s essential to assess the benefits and drawbacks before deciding. THC’s psychoactive effects are always a concern for cannabis-derived products. Some goods on the market don’t reveal their whole ingredients, so users may be ignorant of extra components that may impact adverse effects.
Anticholinergic symptoms including dry mouth, impaired vision, urine retention, tachycardia, constipation, and hypertension are among the most common side effects of cannabis use. In addition to ataxia and cognitive impairment, any THC components can lead to hallucinations in the CNS.
Even if cannabis or CBC has real clinical benefits, the FDA’s final decision to authorize CBC for many health issues mud by faulty studies, patients with multiple sclerosis report reduced anxiety and tremors after consuming cannabis oil infused with the cannabidiol (CBC) (Wlliamson & Evans, 2000). Cannabinoids can also lessen chemo-induced emesis.
Purified CBC does not have the mind-altering and lung irritation-causing side effects of using the complete cannabis plant. Pure CBC also does not impair judgment or ability to drive safely, whether smoked or ingested.
Specific Populations at Risk
Special populations, such as children and teens, pregnant and lactating mothers, and the elderly, are at particular risk of significant adverse effects from cannabis, leading to polypharmacy. As a result, the amount of safe or poisonous CBC differs from producer to producer, manufacturer to product. The entire cannabis plant passes via breast milk.
CBC has been used to treat hyperemesis gravidarum, but doctors do not prescribe it because of a lack of safety recommendations. Adults may benefit from ingesting CBC-infused brownies or cookies, but there are no studies to support or warn against this for children.
CBC products in the house are associated with increased antisocial behavior and a potential safety risk among adolescents who have access to THC products. Due to national research safety rules, finding willing participants in research projects involving newborns, children, teens, and the elderly become more complex.
Mentally ill people are also at risk from using cannabis products, which may worsen their condition. Cannabinoids with THC may activate the same reward system as alcohol, cocaine, and opioids. Thus, patients may become dependent on the drug, leading to worsened irritability, anxiety, sleep problems, and increased appetites.
